Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)
Summary
Prostatype Genomics receives proceeds of approximately SEK 7.3 million before issuing costs.We have recently announced several important advances for the Companys market activities in the United States and our ongoing studies, and the high subscription rate shows strong support for our imminent US market entry. The interim shares are expected to be converted into shares approximately seven banking days after registration with the SCRO.Prostatype Genomics mandated Penser By Carnegie and Advokatfirman Lindahl as financial and legal advisors respectively in connection with the Rights Issue.For further information about Prostatype Genomics, please contact:Prostatype\xae is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Prostatype Genomics in any jurisdiction, neither from Prostatype Genomics nor from someone else.This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction.This announcement does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company.This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the USA, Australia, Belarus, Canada, Hong Kong, Japan, New Zeeland, Russia, Singapore, South Africa, South Korea, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.This disclosure contains information that Prostatype Genomics AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014) and the Swedish Securities Markets Act (2007:528).